🇺🇸 FDA
Patent

US 10398721

Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA

granted A61KA61K31/713A61K47/6455

Quick answer

US patent 10398721 (Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/713, A61K47/6455, A61P, A61P43/00